5755-05-5

Basic information

• Product Name: 7-BroMo-2,3-dihydro-1,4-benzoxazepin-5(4H)-one
• Synonyms: 7-BroMo-2,3-dihydro-1,4-benzoxazepin-5(4H)-one;7-bromo-3,4-dihydrobenzo[f][1,4]oxazepin-5(2H)-one;7-Bromo-3,4-dihydro-2H-1,4-benzoxazepin-5-one;7-bromo-3,4-dihydrobenzo[f][1,4]oxazepin-5(2H)-one(WX142531)
• CAS NO: 5755-05-5
• Molecular Formula: C₉H₈BrNO₂
• Molecular Weight: 242.06932
• Mol File: 5755-05-5.mol
• Article Data: 11

Chemical Properties

• Appearance: white powder
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 7-BroMo-2,3-dihydro-1,4-benzoxazepin-5(4H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 7-BroMo-2,3-dihydro-1,4-benzoxazepin-5(4H)-one(5755-05-5)
• EPA Substance Registry System: 7-BroMo-2,3-dihydro-1,4-benzoxazepin-5(4H)-one(5755-05-5)

Safety Data

• Hazardous Substances Data: 5755-05-5(Hazardous Substances Data)

Usage

General Description

7-Bromo-2,3-dihydro-1,4-benzoxazepin-5(4H)-one is a chemical compound with the molecular formula C8H6BrNO2. It is a heterocyclic compound containing a benzoxazepin ring with a bromine atom attached to the 7th carbon. 7-BroMo-2,3-dihydro-1,4-benzoxazepin-5(4H)-one is used in organic synthesis and medicinal chemistry, where it acts as a starting material for the synthesis of various pharmaceuticals and biologically active molecules. It is also used as a reagent in chemical reactions to introduce the benzoxazepin moiety into different organic compounds. The compound has potential applications in the development of new drugs and biologically active molecules, making it an important chemical in both research and industrial settings.

Upstream product

• 740842-72-2 7-bromo-2,3,4,5-tetrahydrobenzo[f ][1,4]oxazepine hydrochloride 
• 1641-00-5 (2-carbomethoxyphenoxy)acetonitrile 
• 58430-20-9 methyl 5-bromo-2-(cyanomethoxy)benzoate 
• 6329-74-4 5-bromo-2-hydroxybenzamide 
• 74-89-5 methylamine 
• 491-37-2 2,3-dihydro-4H-1-benzopyran-4-one 
• 4068-76-2 5-bromo-2-hydroxy-benzoic acid methyl ester 
• 1167416-56-9 methyl 5-bromo-2-{[2-({[(1,1-dimethylethyl)oxy]carbonyl}amino)ethyl]oxy}benzoate 
• 703-51-5 2,3-dihydro-1,4-benzoxazepin-5(4H)-one 
• 49660-57-3 6-bromochroman-4-one 

Downstream Products

• 1167415-79-3 7-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepine hydrochloride 
• 1167415-78-2 2-[(1-methylethyl)oxy]-5-[3-(2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1,2,4-oxadiazol-5-yl]benzonitrile hydrochloride 
• 740842-73-3 1,1-dimethylethyl 7-bromo-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate 
• 1167416-60-5 1,1-dimethylethyl 7-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate 
• 1167416-59-2 1,1-dimethylethyl 7-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate 
• 1167416-62-7 ethyl 3-[7-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]propanoate 
• 1167416-61-6 ethyl 3-[7-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]propanoate 
• 1167416-63-8 ethyl 4-[7-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]butanoate 
• 1167415-81-7 3-[7-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]propanoic acid 
• 1167415-80-6 3-[7-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]propanoic acid 
• 1167415-82-8 4-[7-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]butanoic acid 
• 1251156-08-7 [7-(6-aminopyridin-3-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl][3-fluoro-2-methyl-4-(methylsulfonyl)-phenyl]methanone 
• 740842-71-1 7-bromo-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine 
• 17775-01-8 2.3.4.5-Tetrahydro-benzo[f][1,4]oxazepine 

Relevant articles and documents

Discovery of 3,4-Dihydrobenzo[ f][1,4]oxazepin-5(2 H)-one Derivatives as a New Class of Selective TNIK Inhibitors and Evaluation of Their Anti-Colorectal Cancer Effects

The Traf2- and Nck-interacting protein kinase (TNIK) is a downstream signal protein of the Wnt/β-catenin pathway and has been thought of as a potential target for the treatment of colorectal cancer (CRC) that is often associated with dysregulation of Wnt/

Deuterium-Substituted Oxazepin Compounds

Described are deuterium-substituted oxazepin compounds of structural Formula I, which are inhibitors/blockers of the late sodium current. Also described are pharmaceutical compositions comprising the deuterium-substituted oxazepin compounds, and methods of use thereof.

PROCESSES FOR PREPARING FUSED HETEROCYCLIC ION CHANNEL MODULATORS

The present disclosure provides processes for the preparation of a compound of formula: which is a selective late sodium current inhibitor. The disclosure also provides compounds that are synthetic intermediates.